drugset
drugset / Trial / NCT02126306

Beta Glucosylceramide for Treatment of NASH

NCT02126306 ↗

Phase 1/2 Completed 23 enrolled Hadassah Medical Organization
RandomizedParallel-groupDouble-blindTreatment

Summary

Oral administration of betaglucosylceramide was shown effective in reducing inflammation in animal models and was found safe in humans.

Timeline

Start
2006-01
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Beta Glucosylceramide Unknown — Oral

Indications

No indication recorded.